Transthyretin Cardiac Amyloidosis Fellowship Grant
The Pfizer Fellowship Grant for Transthyretin Cardiac Amyloidosis is a competitive grant initiative aimed at advancing the professional development of healthcare professionals specializing in the diagnosis and management of ATTR cardiac amyloidosis. This grant is dedicated to enhancing academic and clinical understanding of the disease through research and education. Offered to U.S.-based academic institutions, the program supports fellowship roles for Cardiologists or Heart Failure Advanced Practice Providers, emphasizing a balance of clinical practice, research, and educational outreach. The grant ensures that the supported activities are independent of Pfizer’s commercial interests, focusing on fostering substantial advancements in the field of cardiac health.
Award Range
Not specified - $80,000
Total Program Funding
$80,000
Number of Awards
1
Matching Requirement
No
Eligible Applicants
Additional Requirements
Eligibility is restricted to accredited, U.S.-based academic institutions capable of offering fellowship programs in the specified field of ATTR cardiac amyloidosis. The grant will be awarded to the institution rather than an individual. To qualify, fellowship programs must emphasize independent research and strong mentoring programs. Institutions must ensure that any fellow receiving grant funds is a U.S. worker, which includes U.S. citizens, permanent residents, refugees, asylees, or those holding appropriate non-immigrant visa statuses authorizing employment in the U.S. Importantly, grant funds cannot be used for overhead or indirect costs, and no part of the fellowship can be billed as patient care. Additionally, compliance with the U.S. Physician Payments Sunshine Act and other transparency law requirements is mandatory.
Geographic Eligibility
All
Application Opens
March 27, 2024
Application Closes
June 20, 2024
Grantor
Amanda Stein
Subscribe to view contact details
Subscribe to access grant documents